Aurobindo Pharma records an 85% YoY increase in Q2 consolidated net profit, reaching Rs 757 crore. Q2 revenue stands at Rs 7,219.4 crore, marking a 25.7% growth from the same period last year.
Earnings before interest, taxes, depreciation, and amortization (EBITDA) rises to Rs 1373.5 crore, with a margin of 19%. Robust performance in the US formulations, Europe formulations, and growth markets contributes to the strong financial results.
Research & Development spend at Rs 300 crore, filing 10 Abbreviated New Drug Applications (ANDAs) during the quarter. The Board approves the first interim dividend of 300%, Rs 3.00 per equity share.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
